Skip to main content

Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants

Medically reviewed by Carmen Pope, BPharm. Last updated on June 21, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, June 21, 2024 -- The cumulative risk for advanced gastric cancer varies from 6.5 to 10.3 percent for carriers of germline CDH1 pathogenic/likely pathogenic (P/LP) variants, according to a study published online June 14 in the Journal of the American Medical Association to coincide with presentation at the International Gastric Cancer Linkage Consortium, held from June 13 to 15 in Porto, Portugal.

Carrie E. Ryan, M.D., from the National Institutes of Health in Bethesda, Maryland, and colleagues describe gastric and breast cancer risk estimates for individuals with CDH1 variants in a multicenter retrospective cohort and modeling study. Data were included from 213 families from North America with a germline CDH1 P/LP variant; 883 of the 7,323 individuals had a CDH1 P/LP variant.

The researchers found that the prevalence of gastric cancer was 13.9 percent among those with a CDH1 P/LP variant, and the prevalence of breast cancer was 26.3 percent among female carriers. The estimated hazard ratio for advanced gastric cancer was 33.5 and 3.5 at ages 30 and 70 years, respectively. In male and female carriers, the lifetime cumulative risk for advanced gastric cancer was 10.3 and 6.5 percent, respectively. A carrier with three affected first-degree relatives had a penetrance of about 38 percent in gastric cancer risk estimates based on family history. The hazard ratio for breast cancer among female carriers was 5.7 and 3.9 at ages 30 and 70 years, respectively; the lifetime cumulative risk for breast cancer was 36.8 percent among female carriers.

"These findings inform current management of individuals with germline CDH1 variants," the authors write.

Two authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer

WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published...

Guideline-Concordant Care Less Likely With Non-Hispanic Black Race

TUESDAY, Oct. 29, 2024 -- For older patients with breast cancer, non-Hispanic Black race is associated with increased odds of not receiving guideline-concordant care (GCC) and...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.